The group's principal activity is focused on developing and marketing medical imaging pharmaceutical products. The products include imagent (R), approved by the food and drug administration and two additional contrast agents in development called pH-50 and n1177. Imagent (R), an ultrasound imaging contrast agent improves the visualization of blood vessels for better diagnosis of diseases and assessment of organ function. Ph-50 is a blood pool contrast agent for use in computed tomography (ct) and X-ray imaging to diagnose diseased tissue in the cardiovascular system and other organs. The n1177 enables physicians to precisely locate tumorous nodes by first injecting the material in the vicinity of the tumor and then taking an image using a ct device.
